TScan Therapeutics has realigned its clinical development strategy by prioritizing its hematologic malignancies program, notably pausing enrollment for solid tumor trials. This shift reflects both regulatory alignment and a need to concentrate limited resources on the lead asset TSC-101. Financially, the company continues to operate at substantial losses, with net income declining further in 2025 alongside an expanding cash burn driven by growing R&D activities. Despite a robust liquidity position that supports operations into late 2027, TScan faces significant risks related to manufacturing, intellectual property, and funding that could influence its developmental trajectory and capital allocation decisions.